Research is a core part of Breakthrough Haematology’s approach to blood cancer care. Our specialists are actively involved in clinical trials, translational research, peer-reviewed publications and international collaborations aimed at improving outcomes for patients with lymphoma, CLL, myeloma and other blood disorders.
By combining private specialist care with active research involvement, we aim to provide treatment recommendations that are evidence-based, contemporary and informed by emerging advances in haematology.

